Curis Lifesciences Limited IPO Review
Neutral120-120 · SME
✦
Analyst Verdict
Curis Lifesciences Limited IPO
Neutral
IPO at a Glance
Price Band
120-120
Issue Size
28cr
Min. Investment
₹1,20,000
Opens
2025-11-05
Closes
2025-11-09
Listing
2025-11-12
Category
SME
Key Strengths
✓Experienced promoters with over 15 years in the pharmaceutical industry.
✓Wide product portfolio of 943 approved formulations across multiple therapeutic segments.
✓WHO-GMP certified manufacturing facility ensuring global quality standards.
✓Presence in both domestic and international markets through contract and license manufacturing.
✓Registrations with multiple international health authorities, including Kenya, Philippines, Yemen, and Nigeria
Key Risks
⚠Dependence on a limited number of customers for significant revenue share.\
⚠Any regulatory non-compliance may impact manufacturing operations.
⚠Exposure to litigation risks including trademark and compliance-related cases.
⚠Volatility in raw material prices could affect profitability.
⚠Adverse government or export policy changes may impact business performance.
Frequently Asked Questions
Should I apply for Curis Lifesciences Limited IPO?
Based on our analysis, our rating for Curis Lifesciences Limited IPO is: Neutral. Review the full analysis including strengths, risks, and financials on CheckIPO before making a decision.
What are the key risks of Curis Lifesciences Limited IPO?
Dependence on a limited number of customers for significant revenue share.\ Any regulatory non-compliance may impact manufacturing operations. Exposure to litigation risks including trademark and compliance-related cases.
What are the strengths of Curis Lifesciences Limited IPO?
Experienced promoters with over 15 years in the pharmaceutical industry. Wide product portfolio of 943 approved formulations across multiple therapeutic segments. WHO-GMP certified manufacturing facility ensuring global quality standards.
What is the price band of Curis Lifesciences Limited IPO?
The price band for Curis Lifesciences Limited IPO is 120-120. The IPO has closed.
Full Analysis Available
Financials, DRHP breakdown, peer comparison, shareholding pattern & more